Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free NFX Stock Alerts

Nuformix (NFX) Competitors

Nuformix logo
GBX 0.14 +0.01 (+3.70%)
As of 06:00 AM Eastern
Compare

NFX vs. IXI, FAB, NSCI, GENF, and CLBX

Should you buy Nuformix stock or one of its competitors? Nuformix's main competitors and comparable companies include IXICO (IXI), Fusion Antibodies (FAB), NetScientific (NSCI), Genflow Biosciences (GENF), and Cellbxhealth (CLBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuformix compare to IXICO?

IXICO (LON:IXI) and Nuformix (LON:NFX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Nuformix has lower revenue, but higher earnings than IXICO. Nuformix is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IXICO£7.28M2.23-£3.58M-£1.95N/A
NuformixN/AN/A-£383.40K-£0.03N/A

IXICO has a beta of 0.106, suggesting that its stock price is 89% less volatile than the broader market. Comparatively, Nuformix has a beta of 1.531, suggesting that its stock price is 53% more volatile than the broader market.

Nuformix has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
IXICO-24.98% -16.18% -10.40%
Nuformix N/A -83.53%-17.20%

In the previous week, IXICO had 1 more articles in the media than Nuformix. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Nuformix. IXICO's average media sentiment score of 0.75 beat Nuformix's score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company Overall Sentiment
IXICO Positive
Nuformix Neutral

30.6% of IXICO shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 3.1% of IXICO shares are owned by insiders. Comparatively, 7.5% of Nuformix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

IXICO beats Nuformix on 7 of the 12 factors compared between the two stocks.

How does Nuformix compare to Fusion Antibodies?

Nuformix (LON:NFX) and Fusion Antibodies (LON:FAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Nuformix has higher earnings, but lower revenue than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.03N/A
Fusion Antibodies£1.60M9.57-£4.10M-£1.50N/A

In the previous week, Fusion Antibodies had 2 more articles in the media than Nuformix. MarketBeat recorded 2 mentions for Fusion Antibodies and 0 mentions for Nuformix. Nuformix's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
Nuformix Neutral
Fusion Antibodies Neutral

Nuformix has a beta of 1.531, meaning that its share price is 53% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.244, meaning that its share price is 24% more volatile than the broader market.

Nuformix has a net margin of 0.00% compared to Fusion Antibodies' net margin of -54.45%. Nuformix's return on equity of -83.53% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
Fusion Antibodies -54.45%-97.87%-63.78%

0.1% of Nuformix shares are owned by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are owned by institutional investors. 7.5% of Nuformix shares are owned by company insiders. Comparatively, 5.9% of Fusion Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Nuformix beats Fusion Antibodies on 8 of the 11 factors compared between the two stocks.

How does Nuformix compare to NetScientific?

Nuformix (LON:NFX) and NetScientific (LON:NSCI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Nuformix has a net margin of 0.00% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
NetScientific -182.91%-13.70%-9.42%

In the previous week, Nuformix's average media sentiment score of 0.00 equaled NetScientific'saverage media sentiment score.

Company Overall Sentiment
Nuformix Neutral
NetScientific Neutral

Nuformix has higher earnings, but lower revenue than NetScientific. Nuformix is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.03N/A
NetScientific£1.45M0.00-£2.64M-£0.11N/A

Nuformix has a beta of 1.531, indicating that its share price is 53% more volatile than the broader market. Comparatively, NetScientific has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

0.1% of Nuformix shares are owned by institutional investors. Comparatively, 14.7% of NetScientific shares are owned by institutional investors. 7.5% of Nuformix shares are owned by insiders. Comparatively, 42.4% of NetScientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

NetScientific beats Nuformix on 6 of the 10 factors compared between the two stocks.

How does Nuformix compare to Genflow Biosciences?

Genflow Biosciences (LON:GENF) and Nuformix (LON:NFX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Genflow Biosciences is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
NuformixN/AN/A-£383.40K-£0.03N/A

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Nuformix Neutral

Nuformix has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
Nuformix N/A -83.53%-17.20%

Genflow Biosciences has a beta of 2.285, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.531, indicating that its stock price is 53% more volatile than the broader market.

0.1% of Genflow Biosciences shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 25.8% of Genflow Biosciences shares are owned by insiders. Comparatively, 7.5% of Nuformix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Nuformix beats Genflow Biosciences on 6 of the 9 factors compared between the two stocks.

How does Nuformix compare to Cellbxhealth?

Cellbxhealth (LON:CLBX) and Nuformix (LON:NFX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
Nuformix Neutral

Cellbxhealth has higher revenue and earnings than Nuformix. Nuformix is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M8.15N/A-£3.49N/A
NuformixN/AN/A-£383.40K-£0.03N/A

Cellbxhealth's return on equity of 0.00% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Nuformix N/A -83.53%-17.20%

0.4% of Cellbxhealth shares are owned by institutional investors. Comparatively, 0.1% of Nuformix shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by company insiders. Comparatively, 7.5% of Nuformix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cellbxhealth beats Nuformix on 5 of the 7 factors compared between the two stocks.

Get Nuformix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NFX vs. The Competition

Export
MetricNuformixBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£3.65M£3.98B£7.31B£2.89B
Dividend YieldN/A3.63%2.52%6.22%
P/E Ratio-4.7813.88274.08366.58
Price / SalesN/A1,343.77638.2190,067.79
Price / Cash3.55113.2977.8027.89
Price / Book0.2615.4010.476.41
Net Income-£383.40K-£22.82M£3.49B£5.89B
7 Day Performance-6.67%-1.70%-0.67%0.29%
1 Month Performance-16.67%-6.17%-3.17%6.48%
1 Year PerformanceN/A30.67%15.14%19.36%

Nuformix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NFX
Nuformix
N/AGBX 0.14
+3.7%		N/A+32.0%£3.65MN/AN/A3
IXI
IXICO
N/AGBX 7
-6.7%		N/A-35.7%£15.33M£7.28MN/A89
FAB
Fusion Antibodies
N/AGBX 10.50
+13.5%		N/A-38.2%£13.14M£1.60MN/A48
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45MN/A26
GENF
Genflow Biosciences
N/AGBX 2.21
+0.4%		N/A+30.2%£12.51MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NFX) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel